相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters
Tim A. D. Smith et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett et al.
CLINICAL CANCER RESEARCH (2013)
Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
Yelena Y. Janjigian et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using 18F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth
Leo G. Flores et al.
MOLECULAR IMAGING AND BIOLOGY (2013)
2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363
Juliana Maynard et al.
MOLECULAR IMAGING AND BIOLOGY (2013)
Hypoxia stimulates 18F-Fluorodeoxyglucose uptake in breast cancer cells via Hypoxia inducible Factor-1 and AMP-activated protein kinase
Tim A. D. Smith et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis
Chia-Hsin Chan et al.
CELL (2012)
Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?
Laura Evangelista et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition
Catherine J. Kelly et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
Nicolaos Palaskas et al.
CANCER RESEARCH (2011)
GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1α (HIF-1α) Pathways
Natalie Burrows et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab
Richard W. Cheyne et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Targeting the PI3K signaling pathway in cancer
Kwok-Kin Wong et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
Akt and c-Myc Differentially Activate Cellular Metabolic Programs and Prime Cells to Bioenergetic Inhibition
Yongjun Fan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
Chirayu Shah et al.
CLINICAL CANCER RESEARCH (2009)
18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice
Kristin McLarty et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
mTORC1 Hyperactivity Inhibits Serum Deprivation-Induced Apoptosis via Increased Hexokinase II and GLUT1 Expression, Sustained Mcl-1 Expression, and Glycogen Synthase Kinase 3β Inhibition
Prashanth T. Bhaskar et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Regulation of the Warburg effect in early-passage breast cancer cells
Ian F. Robey et al.
NEOPLASIA (2008)
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines
D. W. Rusnak et al.
CELL PROLIFERATION (2007)
Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking
Heather L. Wiernan et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
Antoinette Hollestelle et al.
MOLECULAR CANCER RESEARCH (2007)
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors
Kenji Kawada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway
Garth Powis et al.
CLINICAL CANCER RESEARCH (2006)
HER2 therapy - Molecular mechanisms of trastuzumab resistance
Rita Nahta et al.
BREAST CANCER RESEARCH (2006)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Waltraud X. Schulze et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
PK Majumder et al.
NATURE MEDICINE (2004)
Akt stimulates aerobic glycolysis in cancer cells
RL Elstrom et al.
CANCER RESEARCH (2004)
Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival
JC Rathmell et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
N Normanno et al.
ANNALS OF ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Specificity and mechanism of action of some commonly used protein kinase inhibitors
SP Davies et al.
BIOCHEMICAL JOURNAL (2000)
分享论文
